ObjectiveTo evaluate the clinical efficacy and safety of artieral infusion chemotherapy combined with 125I seed implantation in treatment of non-small cell lung cancer (NSCLC). MethodsBetween February 2012 to June 2014, 34 patients with unresectable NSCLC received 125I seed implantation, in which 16 patients also received artieral infusion chemotherapy. All the patients were followed up and two months after 125I seed implantation the thoracic CT scanning was carried out in all patients. The response to treatment was evaluated in accordance with Response Evaluation Criteria in Solid Tumors and the accumulated survival rate was analyzed by means of Kaplan-Meier. ResultsThe operation successful rate was 100% and no severe complications were observed. Two months later the thoracic CT scanning showed that patients who only received 125I seed implantation with a total effective rate of 72.2% and those received artieral infusion chemotherapy combined with 125I seed implantation with an effective rate of 87.5%, with no significant difference between two groups in the effective rate (χ2=1.122, P>0.05). Median survival time of two groups was 361 days and 470 days (χ2=2.985, P < 0.05), respectively. Survival rate of 1 year was 43.5% and 83.5%(χ2=4.101, P < 0.05), respectively. ConclusionArtieral infusion chemotherapy combined with 125I seed implantation is safe, reliable and effective in treatment of unresectable NSCLC, which can prolong the patient's survival time.
The iodine-125 (125I) seeds interstitial implantation has the advantages of minimal invasiveness, high local control rate, and few complications; it has attracted worldwide attention. With the application of 3D printing technology in medicine, individualized 3D templates are gradually applied to clinical practice. Individualized 3D templates combining with CT-guided 125I seeds implantation are easy to operate and can not only effectively ensure the consistency and accuracy of preoperative and postoperative dose, but also minimize complications to achieve optimal efficacy. This paper reviews the application of CT-guided implantation of 125I seeds for malignant tumors assisted by individualized 3D template, and further demonstrates the safety and effectiveness of clinical application in 125I seeds implantation to provide a reliable basis for the standardization of 125I seeds implantation.
The widespread implementation of lung cancer screening has led to a marked increase in the detection of early-stage disease, underscoring the clinical need for less invasive treatment strategies. Interventional pulmonology has gained increasing prominence as an alternative for patients who are unsuitable candidates for surgery, leveraging real-time imaging guidance for accurate lesion localization and offering a spectrum of local ablative modalities. In this review, we outline the current evidence regarding thermal and non-thermal ablation, photodynamic therapy, and radioactive seed implantation in the management of early-stage lung cancer. Furthermore, we examine the emerging role of advanced navigation technologies and robotic bronchoscopy platforms in interventional pulmonology. Despite encouraging outcomes, several challenges remain, including heterogeneous treatment selection criteria, the lack of standardized protocols, and limited long-term survival data. Continued technological innovation and high-quality clinical studies are essential to optimize therapeutic efficacy and expand clinical indications. Interventional pulmonology is poised to contribute substantially to personalized and minimally invasive management of early-stage lung cancer, and its integration into multidisciplinary care pathways is likely to become increasingly important in the future.
【摘要】 目的 探討125I粒子植入治療中晚期胰腺癌的臨床并發癥及相關護理措施。 方法 回顧分析2006年10月-2010年4月121例行125I粒子植入治療的胰腺癌患者的臨床治療及護理，采取積極有效的護理措施，預防及處理并發癥，促進患者康復。 結果 121例患者接受放射性125I粒子植入治療后，7例出現胰瘺，13例出現胃腸道反應，經對癥處理和精心護理后均治愈。 結論 125I粒子組織間植入近距離治療中晚期胰腺癌近期療效好、安全、副反應少，良好的護理對改善中晚期胰腺癌患者預后具有重要意義。【Abstract】 Objective To observe the complications in patients with middle and advanced pancreatic carcinoma due to treatment of 125I particle implantation, and the investigate the proper nursing methods. Methods The clinical data including the therapy and nursing methods for the complications in 121 patients with middle and advanced pancreatic carcinoma due to treatment of 125I particle implantation from October 2006 to October 2010 were retrospectively analyzed. The treatment and care for complication were analyzed. Results In the 121 patients who had been treated by 125I particle, pancreatic fistula occurred in seven, and severe gastrointestinal upset was found in 13. The patients with the complications recovered after postoperative treatment and nursing. Conclusion 125I particle implantation for patients with middle and advanced pancreatic carcinoma is effective and safe with a few side reactions; proper nursing is important to improve the prognosis.